Naked humanized antibody targeting CD22 receptor in B-cell lymphomas. Primary use is for the treatment of indolent and aggressive NHLs. Every year there are 56,000 newly diagnosed cases and 25,000 deaths. It is currently in Phase III clinical trials.
Primary use is for the treatment of indolent and aggressive NHLs.
Every year there are 56,000 newly diagnosed cases and 25,000 deaths. It is currently in Phase I clinical trials. Naked humanized antibody targeting CEA-expressing tumors. Primary use is for the treatment of inoperable metastatic solid tumors. It is currently in Phase I clinical trials.